cagrilintide ph | C194H312N54O59S2 | CID 171397054 Development of Cagrilintide, a Long-Acting

Neuroendocrine and stress-axis research (exploring peptide-linked signaling patterns tied to stress physiology)

Landscapes Health & Medical Sciences (AREA) Chemical & Material Sciences (AREA) Organic Chemistry (AREA) Life Sciences & Earth Sciences (AREA) General Health & Medical Sciences (AREA) Medicinal Chemistry (AREA) Proteomics, Peptides & Aminoacids (AREA) Genetics & Genomics (AREA) Molecular Biology (AREA) Biophysics (AREA) Biochemistry (AREA) Gastroenterology & Hepatology (AREA) Engineering & Computer Science (AREA) Bioinformatics & Cheminformatics (AREA) Veterinary Medicine (AREA) Pharmacology & Pharmacy (AREA) Animal Behavior & Ethology (AREA) Public Health (AREA) Neurology (AREA) Neurosurgery (AREA) Biomedical Technology (AREA) Immunology (AREA) Toxicology (AREA) Zoology (AREA) Epidemiology (AREA) Chemical Kinetics & Catalysis (AREA) Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA) General Chemical & Material Sciences (AREA) Psychology (AREA) Psychiatry (AREA) Hospice & Palliative Care (AREA) Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA) Peptides Or Proteins (AREA) Description HEPATOCYTE GROWTH FACTOR MIMICS AS THERAPEUTIC AGENTS DESCRIPTION BACKGROUND OF THE INVENTION Field of the Invention The invention generally relates to methods of using hepatocyte growth factor (HGF) mimics to treat dementia and Parkinson's disease

Either works

10.1016/j.semcdb.2019.01.005 Semin

While basal levels of FOXOs expression are beneficial and necessary for the regulation of some hepatic processes, their upregulation is associated with pathological phenotypes and the worst prognosis

Matricryptins network with matricellular receptors at the surface of endothelial and tumor cells